Doctors FDA Approval Generic Drugs Sales 
The Pharma Data
MARCH 9, 2021
“This first-to-market generic version of AZOPT ® (brinzolamide ophthalmic suspension) 1% in the U.S. provides patients with another important treatment option,” said Christine Baeder, SVP, Chief Operating Officer US Generics, Teva USA. Currently, one in ten generic prescriptions dispensed in the U.S. Source link:[link].
The Pharma Data
DECEMBER 4, 2021
“The launch of our first-to-market authorized generic version of Epiduo® Forte Gel in the U.S. provides patients with another important treatment option,” said Christine Baeder, SVP, Chief Operating Officer US Generics, Teva USA. Epiduo® Forte Gel had annual sales of $253 million in the U.S., IMPORTANT SAFETY INFORMATION.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 7, 2022
“The launch of our first generic version of Revlimid® in the U.S. This product adds to our broad generic portfolio of oncology treatments, which accounts for 73% of the essential medicines in this category, as defined by the World Health Organization.”. Currently, 1 in 12 generic prescriptions dispensed in the U.S. About Teva.
The Pharma Data
MAY 4, 2021
Following the completion of the spin-off of the Upjohn Business (4) in the fourth quarter of 2020, Pfizer now operates as a focused innovative biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sales and distribution of biopharmaceutical products worldwide. Cost of Sales (1). previously $59.4
Pharmaceutical Technology
JANUARY 6, 2023
In Par and Novartis’ agreement, Par gained exclusive rights to market its generic for six months after Novartis’ period of exclusivity finished, beginning September 30, 2014 and ending March 30, 2015. In a press release, the company said a generic launch would damage sales in FY 2023 by $300,000. Gilenya legal drama.
Expert insights. Personalized for you.
52 
Let's personalize your content